Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUGMFN)

Drug Name

CXB-909 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Neurodegenerative disorder	8A20-8A23	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Nerve growth factor (NGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tanezumab	DMJKWMA	Cancer related pain	MG30	Phase 3	[3]
Fasinumab	DM5PRLA	Chronic low back pain	MG30.02	Phase 3	[3]
SAR164877	DMOJLCV	Pain	MG30-MG3Z	Phase 2/3	[4]
CERE-110	DMNW5I9	Alzheimer disease	8A20	Phase 2	[5]
ABT-110	DM1F50I	Chronic pain	MG30	Phase 1	[4]
NsG-0202	DM1ITDN	Alzheimer disease	8A20	Phase 1	[2]
MEDI-578	DMPW21Z	Pain	MG30-MG3Z	Phase 1	[4]
Nerve growth factor	DMHYQ8K	Alzheimer disease	8A20	Terminated	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT01505907) Pharmacokinetic Study of CXB909 in Healthy Male Subjects. U.S. National Institutes of Health.
2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Fate of novel painkiller mAbs hangs in balance.Nat Biotechnol.2011 Mar;29(3):173-4.
5	CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther. 2010 Apr;12(2):240-7.
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.